Navigation Links
Cato T. Laurencin, M.D., Ph.D. to Join Osteotech Board of Directors
Date:9/25/2008

EATONTOWN, N.J., Sept. 25 /PRNewswire-FirstCall/ -- Osteotech, Inc. (Nasdaq: OSTE), a leader in the emerging field of biologic solutions for regenerative medicine, announced today the appointment of Cato T. Laurencin, M.D., Ph.D. to its Board of Directors. Dr. Laurencin joined the Board of Directors effective September 24, 2008 and will serve on both the Audit and the Compensation Committees of the Board of Directors.

Kenneth P. Fallon, III, Chairman of the Board of Directors, commented, "We are excited about the addition of Dr. Laurencin to Osteotech's Board. Cato's experience and expertise as a nationally prominent orthopaedic surgeon will be of great assistance in helping the Board support the Company's new product development initiatives furthering its long-term growth objectives."

Since August 2008, Dr. Laurencin has been the Vice President for Health Affairs and the Dean of the School of Medicine at the University of Connecticut. Dr. Laurencin holds the Albert and Wilda Van Dusen Endowed Chair in Academic Medicine and is the Distinguished Professor of Orthopaedic Surgery at the University of Connecticut. Previously, Dr. Laurencin was the Lillian T. Pratt Distinguished Professor and the Chair of the Department of Orthopaedic Surgery at the University of Virginia and the Orthopaedic Surgeon-in-Chief at the University of Virginia Health System. Dr. Laurencin has been widely published in scholarly journals and holds more than twenty U.S. patents. He is also a member of the Institute of Medicine of the National Academy of Sciences.

Osteotech, Inc., headquartered in Eatontown, New Jersey, is a global leader in providing OsteoBiologic solutions for regenerative medicine to support surgeons and their patients in the repair of the musculoskeletal system through the development of innovative therapy-driven products that alleviate pain, promote biologic healing and restore function. For further information regarding Osteotech or this press release, please go to Osteotech's website at http://www.osteotech.com .


'/>"/>
SOURCE Osteotech, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. MacroChem Announces Michael Zasloff, M.D., Ph.D. Joins Companys Scientific Advisory Board
2. Cynthia Haines, M.D., Named Managing Editor of Physicians Briefing News Wire
3. Poniard Pharmaceuticals Appoints Robert De Jager, M.D., as Chief Medical Officer
4. Nektar Appoints Hoyoung Huh, M.D., Ph.D., to Serve on the Companys Board of Directors
5. BiPar Names Hoyoung Huh, M.D., Ph.D. President and Chief Executive Officer
6. Hsiao Dee Lieu, M.D., F.A.C.C. Named VP of Clinical Research of Nile Therapeutics
7. M. Scott Harris, M.D., Joins Ocera Therapeutics, Inc., as Chief Medical Officer
8. James W. Backstrom, M.D., Named Chief Medical Officer of Foundation Radiology Group
9. David S. Tierney, M.D., Joins Thomas, McNerney & Partners as Entrepreneur-In-Residence
10. Kosan Appoints Pamela S. Cohen, M.D., as Chief Medical Officer
11. Barry Ginsberg, M.D., Ph.D. Elected to Biodels Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... ... 11, 2017 , ... ComplianceOnline’s Medical Device Summit is back for its 4th ... in San Francisco, CA. The Summit brings together current and former FDA office bearers, ... and government officials from around the world to address key issues in device compliance, ...
(Date:10/11/2017)... ... October 11, 2017 , ... Disappearing forests and increased ... of over 5.5 million people each year. Especially those living in larger cities are ... - based in one of the most pollution-affected countries globally - decided to take ...
(Date:10/10/2017)... CA (PRWEB) , ... October ... ... a development-stage cancer-focused pharmaceutical company advancing targeted antibody-drug conjugate (ADC) therapeutics, today ... of targeted HPLN (Hybrid Polymerized Liposomal Nanoparticle), a technology developed in collaboration ...
(Date:10/10/2017)... Calif. , Oct. 10, 2017 SomaGenics ... from the NIH to develop RealSeq®-SC (Single Cell), expected ... for profiling small RNAs (including microRNAs) from single cells ... Program highlights the need to accelerate development of approaches ... "New techniques for measuring levels ...
Breaking Biology Technology:
(Date:4/6/2017)... , April 6, 2017 Forecasts ... ANPR, Document Readers, by End-Use (Transportation & Logistics, Government ... Oil, Gas & Fossil Generation Facility, Nuclear Power), Industrial, ... Other) Are you looking for a definitive ... ...
(Date:4/3/2017)...  Data captured by IsoCode, IsoPlexis Corporation,s ... statistically significant association between the potency of ... objective response of cancer patients post-treatment. The ... cancer patients will respond to CAR-T cell ... to improve both pre-infusion potency testing and cell ...
(Date:3/28/2017)... 28, 2017 The report "Video ... Monitors, Servers, Storage Devices), Software (Video Analytics, VMS), and ... Global Forecast to 2022", published by MarketsandMarkets, the market ... is projected to reach USD 75.64 Billion by 2022, ... The base year considered for the study is 2016 ...
Breaking Biology News(10 mins):